Introducing our Plug & Play Upstream Development Service for Small-sized Biotechs

Learn how this approach allows to efficiently create, screen and isolate high producing clones with reduced cost and time. Other approaches will be described in this case study, such as cell type selection, expression cassette design and super-transfection.

Learn from BDS Team Leader, Cyrielle Corbin, Ph.D. about our mini-pool approach as fast-track process and how we can begin process development in parallel with cell line development, reducing timelines by 10-13 weeks.

A customer sought to increase the titer of a molecule that had proven difficult to express, with a titer insufficient for clinical studies. Learn how our strategy allowed to increase the titer nearly 4-fold after generation of stable pools.

Learn how our customers reduce cost and time by leveraging our CHOZN® cell line and semi-automated approach to mini-pools and reach a 200L scale.

Choose our proprietary CHOZN® platform, which allows for faster, simpler selection and scale-up of high-producing clones.

We help you find the right balance between speed and efficiency, so your clone demonstrates high quality and productivity early on to avoid delays in your clinical trials.

Leverage our innovative approach to mini-pools and confidently run process development and clone selection in parallel and save up to 10 weeks.

Run analytical development in parallel to your cell line development to get you progressing faster. Process transfer between our teams is seamless.

• Full cell line development services from your molecule of interest to the Research Cell Bank of the clones
• Validated cell line development process based on mini-pool approach and QA validated limit dilution cloning
• Variants and signal peptides screening possible during early phases of cell line development
• Monoclonality reports and stability validation in compliance with regulatory expectations
• Add-on services for Analytical method development and product characterization
• Fast-Track process using the mini-pool as early material for process development saving 10-13 weeks on overall project timeline

Learn from BDS Scientist Clémence Justine about factors that must be considered when optimizing recombinant antibody expression.

Learn from Research BDS Scientist Lucie Grinders about our mini-pool approach and how we can begin process development in parallel with cell line development.

Learn from BDS Team Leader, Cyrielle Corbin, Ph.D. how we run steps in parallel for customers who have a very challenging timeline.

Learn from Senior Scientist Helen Hsu, Ph.D. how, with our custom binding assays, and supported with our comprehensive off-the-shelf Fc gamma receptor binding assays, we optimize your mAb production.